{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:16:49Z","timestamp":1794435409884,"version":"4.9.1"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Harm (case series)\u2028Level of Evidence\u20034<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What\u2019s known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Inhaled anticholinergic drugs have been associated with the risk of acute urinary retention (AUR), but this association was never studied under real life circumstances nor was this risk ever quantified.<\/jats:p>\n                    <jats:p>Use of inhaled anticholinergic drugs increases the risk of AUR by 40%. The risk of AUR is highest in recent starters, in patients with benign prostatic hyperplasia (BPH), and in patients receiving their anticholinergic drugs via nebulizer. It might be advisable to consider alternatives for inhaled anticholinergic drugs in COPD patients with BPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To investigate the association between the use of inhaled anticholinergic drugs and the risk of acute urinary retention (AUR) under real\u2010life circumstances.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>We conducted a nested case\u2010control study within a cohort of patients with chronic obstructive pulmonary disease (COPD; as AUR has been associated with the use of inhaled anticholinergic drugs, which are used as first\u2010line treatment for COPD) from the Integrated Primary Care Information (IPCI) database.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The cohort consisted of all patients with COPD aged \u226545 years, registered between 1996 and 2006, with \u226512 months of valid history. Cases were patients with a first diagnosis of AUR.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>To each case, controls were selected matched for age, gender and index date.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Multivariate conditional logistic regression analysis was used to calculate adjusted odds ratios (OR\n                            <jats:sub>adj<\/jats:sub>\n                            ) with 95% confidence intervals (95% CI).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Within the cohort of 22\u00a0579 patients with COPD, 209 cases were identified.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Current use of inhaled anticholinergic drugs was associated with a 40% increase in risk for AUR (OR\n                            <jats:sub>adj<\/jats:sub>\n                            1.40; 95% CI 0.99\u20131.98) compared with non\u2010users.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Among current users, the risk was highest for the recent starters (OR\n                            <jats:sub>adj<\/jats:sub>\n                            3.11; 95% CI 1.21\u20137.98). The risk of long\u2010acting anticholinergic drug tiotropium was not substantially different from that of the short\u2010acting anticholinergic ipratropium.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The association was not dose\u2010dependent, but changed by mode of administration, with nebulizers having the highest risk (OR\n                            <jats:sub>adj<\/jats:sub>\n                            2.92; 95% CI 1.17\u20137.31).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In men with COPD and benign prostatic hyperplasia (BPH) the association was strongest (OR\n                            <jats:sub>adj<\/jats:sub>\n                            4.67; 95% CI 1.56\u201314.0).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Current use of inhaled anticholinergic drugs increases the risk of AUR, especially in patients with BPH or if administered via a nebulizer.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2010.09600.x","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T06:54:31Z","timestamp":1285743271000},"page":"1265-1272","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Inhaled anticholinergic drugs and risk of acute urinary retention"],"prefix":"10.1111","volume":"107","author":[{"given":"Ana S.M.","family":"Afonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia M.C.","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno H.C.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam C.J.M.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy G.O.","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,29]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"1s","article-title":"The pharmacoepidemiology of COPD: recent advances and methodological discussion","volume":"43","author":"Burney P","year":"2003","journal-title":"Eur Respir J Suppl"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200703-456SO"},{"key":"e_1_2_8_4_2","first-page":"833","article-title":"Use of inhaled anticholinergic agents in obstructive airway disease","volume":"52","author":"Restrepo RD","year":"2007","journal-title":"Respir Care"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39377.617269.55"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.13.1547"},{"key":"e_1_2_8_7_2","article-title":"Ipratropium bromide versus the long\u2010acting beta\u20102 agonists for stable chronic obstructive pulmonary disease","volume":"3","author":"Appleton S","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.06.051"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.12.072"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500907"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.65.762.260"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.063271"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc082265"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-10-199311150-00011"},{"key":"e_1_2_8_15_2","first-page":"34s","article-title":"The pharmacoepidemiology of COPD: recent advances and methodological discussion. The Integrated Primary Care Information experience in COPD in the Netherlands","volume":"22","author":"Sturkenboom MC","year":"2003","journal-title":"Eur Respir J"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/9.3.330"},{"key":"e_1_2_8_17_2","volume-title":"Anatomical Therapeutic Chemical (ATC) Index with Defined Daily Dosages","author":"World Health Organization (WHO)","year":"2002"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1634402"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/13.3.294"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831050-00002"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2005.01.012"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200611-1630OC"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116813"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.6.1695"},{"key":"e_1_2_8_25_2","first-page":"E209","article-title":"Oral aphthous\u2010like ulceration due to tiotropium bromide","volume":"12","author":"Vucicevic Boras V","year":"2007","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00238702"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1792-1"},{"key":"e_1_2_8_28_2","first-page":"623","article-title":"Inhaled bronchodilator administration during mechanical ventilation","volume":"49","author":"Duarte AG","year":"2004","journal-title":"Respir Care"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.12.1263"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/pai.2006.19.63"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e3283330862"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.080"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07497.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030656"},{"key":"e_1_2_8_36_2","doi-asserted-by":"crossref","unstructured":"RoehrbornCG SiamiP BarkinJet\u00a0al.The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4\u2010year results from the CombAT study.Euro Urol2010;57:123\u201331","DOI":"10.1016\/j.eururo.2009.09.035"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2010.09600.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2010.09600.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:01:39Z","timestamp":1761753699000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2010.09600.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,29]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1464-410X.2010.09600.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2010.09600.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,29]]},"assertion":[{"value":"2010-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}